<SEC-DOCUMENT>0000950170-23-029851.txt : 20230626
<SEC-HEADER>0000950170-23-029851.hdr.sgml : 20230626
<ACCEPTANCE-DATETIME>20230626160258
ACCESSION NUMBER:		0000950170-23-029851
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230626
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230626
DATE AS OF CHANGE:		20230626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		231042337

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acet-20230626.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-06-26T15:31:24.7566+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:acet="http://www.adicetbio.com/20230626" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ddd550e7-8e7e-434b-88c3-7cb73fb654d4" name="dei:EntityCentralIndexKey" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8">0001720580</ix:nonNumeric><ix:nonNumeric id="F_ba7d4a50-ec76-4079-8e23-12d254014266" name="dei:AmendmentFlag" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8">false</ix:nonNumeric><ix:nonNumeric id="F_a3e11740-6d0d-46d4-9f1c-7220e35202b6" name="dei:SecurityExchangeName" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20230626.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_966a0cd5-7965-43e1-a888-7c4276dacec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-26</xbrli:startDate><xbrli:endDate>2023-06-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a705bd7b-ef31-41c1-9509-1ef7530df108" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa83aaaf-fdf0-4f38-8f10-96dfb0fc2fe6" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 26, 2023</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b10b05d1-ddc0-4a15-9663-bd2fd59d7a12" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c48c560-a2cc-49e5-b249-b2b196c18422" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1551b63b-fecb-4f6f-b37a-0f77994ced9f" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dfd81dc7-5229-4d30-ae8b-b02d2dfc5ff2" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_33b081c2-28c5-4f53-bcd7-54b93b701367" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200 Berkeley Street, 19th Floor</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ded369d1-a232-4898-b8fa-012018b7ba45" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4961136c-fd46-42c9-81f9-0ebf7526c9a9" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_92f34f59-9f3a-4729-9c3a-79c9a8ad6dcb" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f94a70e2-733a-46b2-8ac6-0cb083411655" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8161c965-3a62-411e-be31-a97045cda74f" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">503-9095</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b95cba54-d46a-4594-8b13-9ee1b0461c6c" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c6fe8dc-c8ad-4f3a-9516-2640ae66089b" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4187c092-1275-43e1-93b4-437a8fd860de" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd56faec-6644-48a7-a994-5adf10777059" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f5bbfb2-6e3e-4bcf-86a0-991b2219c26e" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_443c595c-a05b-4975-aa08-f34250ca1a5b" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8af5a0bf-73c4-4c74-8e76-ff201559df30" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a3e11740-6d0d-46d4-9f1c-7220e35202b6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_0f5749e7-cc75-481f-b167-f4a53ef761ef" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_b79e1abb-a79c-41fd-8e6c-721ab314356a" contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 26, 2023, Adicet Bio, Inc. (Adicet or the Company) issued a press release titled &#x201c;Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin&#x2019;s Lymphoma (NHL),&#x201d; a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 26, 2023, the Company issued a press release and presented on safety and efficacy data from the Company&#x2019;s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell non-Hodgkin&#x2019;s lymphoma (NHL). Data highlights as of the May 4, 2023 data-cut date were as follows:<br /></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the 24 efficacy-evaluable patients, 3 received ADI-001 at dose level 1 (DL1) (30 million CAR+ cells), 3 received ADI-001 at dose level 2 (DL2) (100 million CAR+ cells), 6 received ADI-001 at dose level 3 (DL3) (300 million CAR+ cells), 4 received two infusions of ADI-001 at DL3 (two doses of 300 million CAR+ cells, one on day 1 and the second dose on day 7 following a single lymphodepletion), and 8 received ADI-001 at dose level 4 (DL4) (1 billion CAR+ cells).</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients were heavily pretreated with a median of 4 prior lines of therapy (range 2-9), had relatively high tumor burden, and had a poor prognostic outlook based on their median International Prognostic Index (IPI) score. 50% of patients enrolled in the study had progressed on prior CAR T.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADI-001 treatment demonstrated a 71% ORR and 63% CR rate in the study across all dose levels.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADI-001 demonstrated an 83% ORR and 67% CR rate in heavily pre-treated patients (4 median prior lines of therapy) who had progressed on prior CAR T.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADI-001 demonstrated a 6-month CR rate consistent with autologous CAR T when factoring number of prior lines of therapy and percent of patients enrolled in the study who progressed on prior CAR T.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adicet selected the recommended Phase 2 dose (RP2D) as 1 billion CAR positive cells (DL4).</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the RP2D (DL4) (with 4 median prior lines of therapy, 38% post-CAR T) the 6-month CR rate was 25%. At this dose level, in patients who had progressed on prior CAR T, the CR rate was 67% and the 6-month CR rate was 33%.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expansion and persistence of ADI-001 at the RP2D exceed values reported for approved autologous CD19 CAR T cell therapy. DL4 demonstrated a mean Cmax of 483 cells/ul with a mean time-to-peak at approximately day 9 and demonstrated persistence through day 28 with a mean concentration of 21 cells/ul.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADI-001 was generally well-tolerated in the study and there were no occurrences of dose-limiting toxicities or graft vs host disease (GvHD). Of the 24 patients evaluable for safety, there was 1 report of Grade 3 or higher CRS and 1 report of Grade 3 or higher ICANS.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May, the Company completed a Type B meeting with the FDA and expects to transition the ADI-001 program into a potentially pivotal Phase 2 study in post- CAR T LBCL in the first half of 2024.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 1 &#x2013; Summary of Phase 1 ADI-001 Preliminary Efficacy Data as of the May 4, 2023 data-cut date:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACTIVE/123834403</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:86.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.378%;"></td>
    <td style="width:13.397%;"></td>
    <td style="width:13.397%;"></td>
    <td style="width:14.437%;"></td>
    <td style="width:14.437%;"></td>
    <td style="width:15.457%;"></td>
    <td style="width:16.497%;"></td>
   </tr>
   <tr style="height:64.8pt;">
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Median No. of Prior Lines</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-CAR T Patients</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ORR (%)</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CR Rate (%)</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3-month</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CR Rate (%)</span></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6-month</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CR Rate (%)</span></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL4 (RP2D)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/8 (37.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/8 (75.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/8 (62.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4/8 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/8 (25.0%)</span></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL4 (RP2D)</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post CAR T</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/3 (100.0%)</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/3 (100.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/3 (67.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/3 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/3 (33.3%)</span></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Doses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/24 (50%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17/24 (70.8%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15/24 (62.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/24 (37.5%)</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4/24 (16.7%)</span></p></td>
   </tr>
   <tr style="height:64.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post CAR T</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Doses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/12 (100.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/12 (83.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/12 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4/12 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/12 (16.7%)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 2 &#x2013; Summary of Phase 1 ADI-001 Safety Data in Efficacy Evaluable Patients as of the May 4, 2023 data-cut date*:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.9%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:8.6%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:8.6%;"></td>
    <td style="width:7.52%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL1(N=3)</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL2(N=3)</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL3(N=6)</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL3 X2(N=4)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DL4(N=8)</span></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total  (N=24)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:70.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gr&gt;=3</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (16.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (16.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (100.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11 (45.8%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (4.2%)</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ICANS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (25.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (25.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (12.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (12.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (4.2%)</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GvHD</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DLT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Infection</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (25.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (37.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (25.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11 (45.8%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6 (25.0%)</span></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAE-TEAE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (66.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (37.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (25.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 (50.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 (41.7%)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACTIVE/123834403</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.9%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:8.6%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:7.52%;"></td>
    <td style="width:6.46%;"></td>
    <td style="width:8.6%;"></td>
    <td style="width:7.52%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related SAE-TEAE</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (33.3%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (50.0%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (33.3%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50.0%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (50.0%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (37.5%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (25.0%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 (41.7%)</span></p></td>
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 (29.2%)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*Safety assessment was performed using the Common Terminology Criteria for Adverse Events (v5) and the American Society for Transplantation and Cellular Therapy criteria.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The disclosure under this Item 8.01 contains &#x201c;forward-looking statements&#x201d; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001; the expected progress, timing and success of the Phase 1 study of ADI-001 in relapsed/refractory NHL patients, including the identification of a recommended Phase 2 dose and the expected performance compared to approved CD19 autologous CAR T therapy; the plan to transition ADI-001 into a potentially pivotal Phase 2 study in the first half of 2024; and expected timing of additional data in post-CAR T LBCL patients in the second half of 2024.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s preclinical or clinical studies, business operations and ability to raise additional capital; Adicet&#x2019;s ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet&#x2019;s actual results to differ from those contained in the forward-looking statements, see the section titled &#34;Risk Factors&#34; in Adicet&#x2019;s most recent Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission. All disclosure under this Item 8.01 is as of the date of this Form 8-K, and Adicet undertakes no duty to update this information unless required by law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.373%;text-indent:0.0%;font-size:10.0pt;margin-top:1.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01. 	Exhibits.</span></p>
  <p style="margin-left:0.4%;text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press release issued by Adicet Bio, Inc. on June 26, 2023, furnished herewith.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACTIVE/123834403</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.06%;"></td>
    <td style="width:44.44%;"></td>
    <td style="width:6.06%;"></td>
    <td style="width:43.44%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADICET BIO, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 26, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Nick Harvey</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;Name:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;Title:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nick Harvey<br />Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACTIVE/123834403</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>acet-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img94724212_0.jpg" alt="img94724212_0.jpg" style="width:239px;height:67px;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin&#x2019;s Lymphoma (NHL)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.267%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Six-month CR rate consistent with autologous CAR T cell therapy</font></p>
  <p style="margin-left:4.267%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved CD19 autologous CAR T therapy</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Plan to transition ADI-001 program into potentially pivotal Phase 2 study in post-CAR T large B-cell lymphoma (LBCL) patients in first half of 2024</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical update from additional post-CAR T LBCL patients expected in second half of 2024</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company to host investor webcast on Monday, June 26 at 4:30pm ET</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REDWOOD CITY, Calif. &amp; BOSTON &#x2013; June 26, 2023 &#x2013; Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company&#x2019;s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;These data are exciting and beyond what one might expect to see given that patients enrolled in the study were heavily pre-treated,&#x201d; said Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio. &#x201c;Autologous CD19 CAR T therapies were studied on CAR T na&iuml;ve patients with a median of 3 prior lines of therapy.  In contrast, the ADI-001 Phase 1 trial enrolled patients with a median of 4 lines of prior therapy and, importantly, 50% had previously progressed on autologous CAR T therapy.  Despite the advanced nature of the patients at baseline in the ADI-001 Phase</font><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 study, at our recommended Phase 2 dose (DL4) ADI-001 demonstrated an overall CR rate of 63%, a 6-month CR rate of 25%, and in patients that had progressed following autologous CD19 CAR T therapy, the CR rate of ADI-001 was 67% with a 6-month CR rate of 33%</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Added Galimi, &#x201c;We plan to transition the ADI-001 program into a potential pivotal Phase 2 study in post-CAR T LBCL in the first half of 2024. In addition, we expect to provide a clinical update which will include efficacy, 6-month CR rate, and safety data, from  additional post-CAR T LBCL patients in the second half of 2024.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;The autologous CD19 CAR T market is estimated to have an annual run rate in excess of $2.2 billion and is growing given recent approvals in the second line setting. Unfortunately, approximately 60-70% of these patients progress, which represents a significant unmet medical need,&#x201d; said Chen Schor, President and Chief Executive Officer of Adicet Bio. &#x201c;In May we met with the FDA and discussed the design of our first potentially pivotal Phase 2 study with an accelerated approval pathway. We are very encouraged by these data and look forward to advancing ADI-001 into the next stage of clinical development and progressing our pipeline of </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">novel gamma delta T cell product candidates in both hematologic malignancies and solid tumors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Data highlights as of the May 4, 2023 data-cut date were as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Of the 24 efficacy-evaluable patients, 3 received ADI-001 at dose level 1 (DL1) (30 million CAR+ cells), 3 received ADI-001 at dose level 2 (DL2) (100 million CAR+ cells), 6 received ADI-001 at dose level 3 (DL3) (300 million CAR+ cells), 4 received two infusions of ADI-001 at DL3 (two doses of 300 million CAR+ cells, one on day 1 and the second dose on day 7 following a single lymphodepletion), and 8 received ADI-001 at dose level 4 (DL4) (1 billion CAR+ cells).</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Patients were heavily pretreated with a median of 4 prior lines of therapy (range 2-9), had relatively high tumor burden, and had a poor prognostic outlook based on their median International Prognostic Index (IPI) score. 50% of patients enrolled in the study had progressed on prior CAR T.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 treatment demonstrated a 71% ORR and 63% CR rate in the study across all dose levels.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 demonstrated an 83% ORR and 67% CR rate in heavily pre-treated patients (4 median prior lines of therapy) who had progressed on prior CAR T.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 demonstrated a 6-month CR rate consistent with autologous CAR T when factoring number of prior lines of therapy and percent of patients enrolled in the study who progressed on prior CAR T. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adicet selected the recommended Phase 2 dose (RP2D) as 1 billion CAR positive cells (DL4).</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the RP2D</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,67,119,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(DL4) (with 4 median prior lines of therapy, 38% post-CAR T) the 6-month CR rate was 25%.</font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> At this dose level, in patients who had progressed on prior CAR T, the CR rate was 67% and the 6-month CR rate was 33%</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The expansion and persistence of ADI-001 at the RP2D exceed values reported for approved autologous CD19 CAR T cell therapy. DL4 demonstrated a mean </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cmax of 483 cells/ul with a mean time-to-peak at approximately day 9 and demonstrated persistence through day 28 with a mean concentration of 21 cells/ul.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 was generally well-tolerated in the study and there were no occurrences of dose-limiting toxicities or graft vs host disease (GvHD). Of the 24 patients evaluable for safety, there was 1 report of Grade 3 or higher CRS and 1 report of Grade 3 or higher ICANS.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In May, the Company completed a Type B meeting with the FDA and expects to transition the ADI-001 program into a potentially pivotal Phase 2 study in post- CAR T LBCL in the first half of 2024.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table 1 &#x2013; Summary of Phase 1 ADI-001 Preliminary Efficacy Data as of the May 4, 2023 data-cut date:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.318%;"></td>
    <td style="width:13.397%;"></td>
    <td style="width:13.897%;"></td>
    <td style="width:14.397%;"></td>
    <td style="width:14.237%;"></td>
    <td style="width:15.097%;"></td>
    <td style="width:16.657%;"></td>
   </tr>
   <tr style="height:64.8pt;">
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Median No. of Prior Lines</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Post-CAR T Patients</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ORR (%)</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CR Rate (%)</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3-month</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CR Rate (%)</font></p></td>
    <td style="border-top:0.75pt solid rgba(104,107,130,1);background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6-month</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CR Rate (%)</font></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL4 (RP2D)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3/8 (37.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6/8 (75.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5/8 (62.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4/8 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2/8 (25.0%)</font></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL4</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(RP2D)</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Post CAR T</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3/3 (100.0%)</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3/3 (100.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2/3 (67.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1/3 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1/3 (33.3%)</font></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All Doses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12/24 (50%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17/24 (70.8%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15/24 (62.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9/24 (37.5%)</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4/24 (16.7%)</font></p></td>
   </tr>
   <tr style="height:64.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(104,107,130,1);padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Post CAR T</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All Doses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12/12 (100.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10/12 (83.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8/12 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4/12 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.05in;border-right:0.75pt solid rgba(104,107,130,1);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:middle;padding-bottom:0.05in;border-bottom:0.75pt solid rgba(104,107,130,1);padding-right:0.1in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2/12 (16.7%)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table 2 &#x2013; Summary of Phase 1 ADI-001 Safety Data in Efficacy Evaluable Patients as of the May 4, 2023 data-cut date*:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.08%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
    <td style="width:7.16%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL1(N=3)</font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL2(N=3)</font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL3(N=6)</font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL3 X2(N=4)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DL4(N=8)</font></p></td>
    <td colspan="2" style="border-top:1pt solid rgba(107,110,132,1);background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total  (N=24)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:70.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any Grade</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gr&gt;=3</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CRS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (16.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (16.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 (100.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11 (45.8%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (4.2%)</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ICANS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (12.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (12.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (4.2%)</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">GvHD</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DLT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Infection</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (37.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11 (45.8%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6 (25.0%)</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SAE-TEAE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 (66.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (37.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10 (41.7%)</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;border-left:1pt solid rgba(107,110,132,1);padding-left:0.1in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Related SAE-TEAE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (33.3%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (50.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 (37.5%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2 (25.0%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10 (41.7%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:1pt solid rgba(107,110,132,1);word-break:break-word;white-space:pre-wrap;padding-left:0.014in;vertical-align:middle;border-bottom:1pt solid rgba(107,110,132,1);padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7 (29.2%)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">*Safety assessment was performed using the Common Terminology Criteria for Adverse Events (v5) and the American Society for Transplantation and Cellular Therapy criteria.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Webcast/ Conference Call Information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adicet will host a webcast presentation on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Monday, June 26 at 4:30pm ET</font><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The</font><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">live webcast of the presentation can be accessed by registering under &#x201c;Presentations &amp; Events&#x201d; in the investors section of the Company&#x2019;s website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To participate via telephone, please join by dialing 972-9349-2674 (domestic) or 1-646-876-9923 (international) and referencing the conference ID 97293492674. An archived replay will be available for 30 days following the presentation. The archived webcast will be available on the Company's website beginning approximately two hours after the event.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">About ADI-001</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL.</font><font style="color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">About the GLEAN Study</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(10,10,10,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Phase 1 study is an open-label, multi-center study of ADI-001 enrolling adults diagnosed with B-cell malignancies who have either relapsed, or are refractory to, at least two prior regimens. The primary objectives of the study are to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ADI-001, and to determine optimal dosing as a monotherapy. For more information about the clinical study design, please visit </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">www.clinicaltrials.gov (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NCT04735471</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">About Adicet Bio, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at </font><font style="background-color:rgba(0,0,0,0);color:rgba(218,30,38,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">https://www.adicetbio.com</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Available Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br>Adicet announces material information to the public about the Company, its product candidates and clinical trials, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts, the investor relations section of the Company website at investor.adicetbio.com and the Company&#x2019;s Twitter account (@AdicetBio), in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forward-Looking Statements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br>This press release contains &#x201c;forward-looking statements&#x201d; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001; the expected progress, timing and success of the Phase 1 study of ADI-001 in relapsed/refractory NHL patients, including the identification of a recommended Phase 2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">dose and the expected performance compared to approved CD19 autologous CAR T therapy; the plan to transition ADI-001 into a potentially pivotal Phase 2 study in the first half of 2024; and expected timing of additional data in post-CAR T LBCL patients in the second half of 2024.  Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s preclinical or clinical studies, business operations and ability to raise additional capital; Adicet&#x2019;s ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet&#x2019;s actual results to differ from those contained in the forward-looking statements, see the section titled &#x201c;Risk Factors&#x201d; in Adicet&#x2019;s most recent Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adicet Bio., Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Investor and Media Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Anne Bowdidge</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">abowdidge@adicetbio.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Janhavi Mohite</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stern Investor Relations, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">212-362-1200</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">janhavi.mohite@sternir.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img94724212_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94724212_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +,# 2(  A$! Q$!_\0
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MG-QC*Z75':?#CQ6_BSPNEQ<NIOX',5S@8R>H;'N/U!KJ;N1H;*>1.&2-F'U
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acet-20230626.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-26T15:31:24.7373+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20230626" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20230626" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20230626_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20230626_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acet-20230626_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-26T15:31:24.7548+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20230626.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>acet-20230626_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-26T15:31:24.7800+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140689618193968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 26,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street, 19th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-9095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>acet-20230626_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20230626.xsd" xlink:type="simple"/>
    <context id="C_966a0cd5-7965-43e1-a888-7c4276dacec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_ddd550e7-8e7e-434b-88c3-7cb73fb654d4">0001720580</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_ba7d4a50-ec76-4079-8e23-12d254014266">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_a3e11740-6d0d-46d4-9f1c-7220e35202b6">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_a705bd7b-ef31-41c1-9509-1ef7530df108">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_fa83aaaf-fdf0-4f38-8f10-96dfb0fc2fe6">2023-06-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_b10b05d1-ddc0-4a15-9663-bd2fd59d7a12">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_8c48c560-a2cc-49e5-b249-b2b196c18422">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_1551b63b-fecb-4f6f-b37a-0f77994ced9f">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_dfd81dc7-5229-4d30-ae8b-b02d2dfc5ff2">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_33b081c2-28c5-4f53-bcd7-54b93b701367">200 Berkeley Street, 19th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_ded369d1-a232-4898-b8fa-012018b7ba45">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_4961136c-fd46-42c9-81f9-0ebf7526c9a9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_92f34f59-9f3a-4729-9c3a-79c9a8ad6dcb">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_f94a70e2-733a-46b2-8ac6-0cb083411655">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_8161c965-3a62-411e-be31-a97045cda74f">503-9095</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_b95cba54-d46a-4594-8b13-9ee1b0461c6c">Not applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_4c6fe8dc-c8ad-4f3a-9516-2640ae66089b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_4187c092-1275-43e1-93b4-437a8fd860de">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_dd56faec-6644-48a7-a994-5adf10777059">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_0f5bbfb2-6e3e-4bcf-86a0-991b2219c26e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_443c595c-a05b-4975-aa08-f34250ca1a5b">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_8af5a0bf-73c4-4c74-8e76-ff201559df30">ACET</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_0f5749e7-cc75-481f-b167-f4a53ef761ef">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_966a0cd5-7965-43e1-a888-7c4276dacec8"
      id="F_b79e1abb-a79c-41fd-8e6c-721ab314356a">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %R VE8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !<@-I66.$:3>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'%8#B;-96.G%@8K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/
MGT"M#E+[B,_1!XQD,=U-KA^2U&'#3D1! B1]0J=2.2>&N7GPT2F:G_$(0>D/
M=400G#?@D)11I& !%F$ELJXU6NJ(BGR\X(U>\>$S]AEF-&"/#@=*4)45L&Z9
M&,Y3W\(-L, (HTO?!30K,5?_Q.8.L$MR2G9-C>-8CG7.S3M4\+;;ON1U"SLD
M4H/&^5>RDLX!-^PZ^;5^>-P_L4YP41>\*42S%UQR(>_K]\7UA]]-V'EC#_8?
M&U\%NQ9^W47W!5!+ P04    " !<@-I6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %R VE;Q-!WGI00  /41   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9AK;^I&$(;_RLJMJG,D$FP3;BD@$9*TZ<D%!=HCM>J'Q1Y@%=OK[JY#^/>=
M-6#3U(SY C9X7S\[.SOOV(.-5&]Z#6#81QPE>NBLC4FOFTT=K"'F^E*FD. _
M2ZEB;O!4K9HZ5<##?% <-7W7[31C+A)G-,A_FZK10&8F$@E,%=-9''.UO8%(
M;H:.YQQ^>!6KM;$_-$>#E*]@!N;W=*KPK%FHA"*&1 N9, 7+H3/VKF_\CAV0
M7_&'@(T^.F9V*@LIW^S)0SAT7$L$$03&2G#\>H<)1)%50HY_]J).<4\[\/CX
MH'Z?3QXGL^ :)C+Z+D*S'CH]AX6PY%ED7N7F5]A/J&WU AGI_)-M=M>V?8<%
MF38RW@]&@E@DNV_^L0_$T8"K4P/\_0 _Y][=**>\Y8:/!DINF+)7HYH]R*>:
MCT8XD=A5F1F%_PH<9T:W,L@PR(:-DY#=)4:8+7M(=JN-41LT#=[$7MH,]H(W
M.T'_A.!O67+)_$Z#^:[?^N_P)K(5@'X!Z.=ZK1-Z$_D.BOTU7FBC< G_KB+:
M*5Q5*]B\OM8I#V#H8.)J4._@C'[ZP>NX/Q-\K8*O1:F7 9QO4ZB"HX?W+KX1
M$%<%Q!6I,D:",*>XC_BJBH(>O^21!H*C77"TSPO&%)20-J%"AFE9&1=:J4BC
MNCSJ%&@=4G"?VZ^P$C:3D/&9QY5@M,XX% $6RQLA&[A1@DL"K5N@=<]!FV#@
M%(]0-80/]@VV57"TDNNZ7M=WVSV7P.H56+USL.YB4"N1K-@O.-ZLV43&*4\J
MX6@]HS(JQ_H%5I^4F4&0*6$$:#8.,.%%!.PYBQ>@JI!H+0S71:O7:O<)+L\M
M2ZE[3L P*Z1*I<H+:(/-#&X )A4&+L,%QG66867>U:C?WE&01_7>.P=RSC_8
M0X@9)Y8BR$F)(-9(]C"(+;?M=[L485GP/;)>'PC'88C56C<.!^P1KV,O277L
M:$GL4=@-J#=L!K:X( K=LL&\/F;S?22EHK!+'_#H2OX9>V+/<-GG<E-MH[3<
MC43O3RBRTAP\NKI_)BLR<JKDNTB"ZHC2FD]C"JWT"X\N\Y_1ICAK+(%_BO3T
M-J$57=_S.A1;:1@>7>GS!1QCJWL:A1;XTFF[7RF4TB \NJX_R@"C,EW+A*IU
M-2)MMW71=_MMBJCT!N\L<SAJ%1O,MLG8JSW""F$QO79>"PK"DUY;<Y=G:1A/
MTPA+U"*BS,,KW<.C2_YW] X#B;6Q.$OVM4]7LM%"=3V37_J&3U?VF<0)HJ.A
MQS[ASE2"1Y5=+JU2RU-:A$_7\ZF"BP## U@:=JTM=I>XL"_+977BU>C5DAT]
M"]!U_']D#UIG2%8+2,O6 I8FX)]E G<?;(X]IA:YL>Z:X4HN6JV6J[0 GR[7
M<V&P39)+YOE?%E_9OH>J;.)JE.R^P3G-C S>&BSEBKWS* /VHWMINT^6XCKH
M-5<D=^D//EW-,8JAW1>S;;R0U;N"%AA/[N842>D&/EW,#R'#M0W6/%G!R9I6
M(_3\\ES9R36/'N+M"Y$G;MMNS2)8HHY[V<6)JMT[AMV)D6G^7+^0QL@X/UP#
MQWU@+\#_EU*:PXE]55"\Z1G]"U!+ P04    " !<@-I6GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 7(#:5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !<@-I66.$:3>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !<@-I6F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %R VE;Q
M-!WGI00  /41   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !<@-I6GZ ;\+$"  #B#   #0
M    @ 'H#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %R VE:7BKL<P
M !,"   +              "  <0/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M %R VE8ZJJ+G0 $  #P"   /              "  :T0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !<@-I6)!Z;HJT   #X 0  &@
M@ $:$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !<
M@-I699!YDAD!  #/ P  $P              @ '_$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  !)%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acet-20230626.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  acet-20230626.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="acet-20230626.htm">acet-20230626.htm</File>
    <File>acet-20230626.xsd</File>
    <File>acet-20230626_lab.xml</File>
    <File>acet-20230626_pre.xml</File>
    <File>acet-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acet-20230626.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "acet-20230626.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20230626_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20230626_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20230626.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20230626",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20230626.htm",
      "contextRef": "C_966a0cd5-7965-43e1-a888-7c4276dacec8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20230626.htm",
      "contextRef": "C_966a0cd5-7965-43e1-a888-7c4276dacec8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.adicetbio.com/20230626/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-23-029851-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-029851-xbrl.zip
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MG_^+_18E+H_85Y[^$/G"XLRS!J4NN?MT#4J\@9UQ&ONX7B28.V:>C-V#=O^
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M:<-(9KFC(C4=%:7\-D_2FP]O9\LG04DT6-G,%X!?A>7DFRO'&[)(L.!3H6.
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MY8' 4 -&39_;<@+N\FS08B?!8JYPO4W!"DV)%03N7*',!79;\N#>Y)E2_@5
M$H%<,\LS6>S9-@*I%R;,HL#.!*R26#8/^+3&B2EJB]J^!-V\Y-EZCK7D^Q+K
M>9%<1^W_  S/\61P"C2GZRM@TM]MC!'!& KV5DW!;QH+$NK=")4/<X'^]=;*
M><U63FW3Q"]W*LV_\<CG$\D^*%P#2?5NI'J))U99Z29<%#7XY^B$W9^4.TZG
MV=WO-)U.NTTRO1N9_F[YH!4:/O@KGGB/9$+6\;ZMX^JD]KZ7IBZ%\>TF\NO*
M?&]>#Y4W^^5/;U[[:1C\\A]02P$"% ,4    " !<@-I6Q/2R5:DG  "^N (
M$0              @ $     86-E="TR,#(S,#8R-BYH=&U02P$"% ,4
M" !<@-I6D )G:@X#  "G"0  $0              @ '8)P  86-E="TR,#(S
M,#8R-BYX<V102P$"% ,4    " !<@-I6CR6PH (&  #!-@  %0
M    @ $5*P  86-E="TR,#(S,#8R-E]L86(N>&UL4$L! A0#%     @ 7(#:
M5N5JEP7"!   ,"@  !4              ( !2C$  &%C970M,C R,S V,C9?
M<')E+GAM;%!+ 0(4 Q0    ( %R VE:O8J/4 B$  +-' @ /
M  "  3\V  !A8V5T+65X.3E?,2YH=&U02P4&      4 !0!! 0  ;E<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
